Assessing ADMA Biologics: Insights From 4 Financial Analysts
Assessing ADMA Biologics: Insights From 4 Financial Analysts
评估adma biologics：来自4个财务分析师的见解
Ratings for ADMA Biologics (NASDAQ:ADMA) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
过去三个月ADMA Biologics (纳斯达克:adma biologics)的评级来自4位分析师，展示了看好和看淡的混合观点。
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
在下表中，您将找到他们最近的评级摘要，揭示了过去30天内情绪的变化，并将它们与前几个月进行比较。
In the assessment of 12-month price targets, analysts unveil insights for ADMA Biologics, presenting an average target of $16.75, a high estimate of $20.00, and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 42.55% from the previous average price target of $11.75.
在评估12个月的价格目标时，分析师揭示了ADMA Biologics的洞见，提出了16.75美元的平均目标，20.00美元的高估值和14.00美元的低估值。目前的平均值比之前的平均价格目标11.75美元上涨了42.55%。
Exploring Analyst Ratings: An In...
分析师评级...
登录免费看全文
登录/注册